Product Datasheet

GAPDH Antibody NB300-320

Unit Size: 0.1 mg

Store at -20C. Avoid freeze-thaw cycles.



Reviews: 2 Publications: 69

Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NB300-320

Updated 4/13/2025 v.20.1

Earn rewards for product reviews and publications.

Submit a publication at www.novusbio.com/publications Submit a review at www.novusbio.com/reviews/destination/NB300-320



NB300-320

GAPDH Antibody

Product Information	
Unit Size	0.1 mg
Concentration	0.5 mg/ml
Storage	Store at -20C. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.02% Sodium Azide
Isotype	IgG
Purity	Immunogen affinity purified
Buffer	Tris saline (20 mM Tris pH 7.3, 150 mM NaCl), 0.5% BSA
Target Molecular Weight	36 kDa
Product Description	
Host	Goat
Gene ID	2597
Gene Symbol	GAPDH
Species	Human, Mouse, Rat, Canine, Drosophila, Insect
Reactivity Notes	Drosophilia reactivity reported in scientific literature (PMID: 28888970 and PMID: 33046910). Canine reactivity reported in scientific literature (PMID: 30030415). Use in Mouse reported in scientific literature (PMID:32771388).
Immunogen	This GAPDG antibody was developed against the peptide sequence C-HQVVSSDFNSDT corresponding to C-Terminus according to NP_002037.2.
Product Application Details	
Applications	Western Blot, Simple Western, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin, Peptide ELISA, Single Cell Western
Recommended Dilutions	Western Blot 0.001 - 0.003 ug/mL, Simple Western, Immunohistochemistry, Immunocytochemistry/ Immunofluorescence 10 ug/mL, Immunohistochemistry- Paraffin 2.5 ug/mL, Peptide ELISA Detection limit 1:128000, Single Cell Western 100 ug/ml
Application Notes	Single Cell Western reported by an internal validation on HeLa-GFP cells at a concentration of 100 ug/ml

Images

Western Blot: GAPDH Antibody [NB300-320] - Staining of Human Liver (A) and Tonsil (B) with antibody at 0.001 ug/mL and Rat Brain lysate (C) with antibody at 0.3 ug/mL (35 ug protein in RIPA buffer). Detected by chemiluminescence. Approx. 37 kDa band observed in Rat Brain lysates and approx. 35 kDa in Human Liver and Tonsil lysates (calculated MW of 36.1 kDa according to Human NP_002037.2 and 35.8 kDa according to Rat NP_058704.1).











320] - Immunofluorescence analysis of paraformaldehyde fixed A549 cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL), showing cytoplasmic and vesicle staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL). Strong expression of the protein seen in the cytoplasm and vesicles of A549 cells.

Immunocytochemistry/Immunofluorescence: GAPDH Antibody [NB300-

Immunohistochemistry-Paraffin: GAPDH Antibody [NB300-320] -Upregulation of GAPDH and Tom20 in C6 gliomas. A small glioma labeled with antibodies against GAPDH. The brightness and contrast have been increased. Image collected and cropped by CiteAb from the following publication (https://www.biomedcentral.com/1756-0500/8/207), licensed under a CC-BY license.

Upregulation of GAPDH & Tom20 in C6 gliomas. a A section of rat brain stained with hematoxilin & eosin to show a glioma produced by implantation of C6 cells in the right caudate nucleus. In this case, cells also grew in the region of the syringe needle track through the cortex. (b-d). A small glioma labeled by bisbenzamide (b) & with antibodies against Tom20 (c) & GAPDH (d). The brightness & contrast have been increased. e Illustration of a strip perpendicular to the rim of a glioma (labeled with bisbenzamide) & along which intensity profiles were measured. f, g Tom20 & GAPDH fluorescence along such a strip (barely visible without enhancement). The graphs show the raw intensity values given by ImageJ. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/26032618), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GAPDH Antibody [NB300-320] - PAR2 causes contraction (C) of smooth muscle cells from human prostate. (A & B) Decrease in diameter of collagen hydrogels after PAR2 activation with SLIGKV (80 µM). (C) Representative western blot & (D) densitometry showing time dependent increase in level of phosphorylated MLC20 in PSMC after PAR2 is activated. Data represent mean ± SEM of at least three independent experiments. Diameter of collagen hydrogels were measured in ImageJ (version 1.50i) & significance analyzed in Prism (version 7.04) with one way ANOVA followed by Tukey's multiple comparison test. *P < 0.05, **P < 0.01 Image collected & cropped by CiteAb from the following publication

(https://pubmed.ncbi.nlm.nih.gov/31198907), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Page 3 of 10 v.20.1 Updated 4/13/2025











Immunocytochemistry/ Immunofluorescence: GAPDH Antibody [NB300d 320] - Upregulation of GAPDH & Tom20 in C6 gliomas. a A section of rat brain stained with hematoxilin & eosin to show a glioma produced by implantation of C6 cells in the right caudate nucleus. In this case, cells also grew in the region of the syringe needle track through the cortex. (b-d). A small glioma labeled by bisbenzamide (b) & with antibodies against Tom20 (c) & GAPDH (d). The brightness & contrast have been increased. e Illustration of a strip perpendicular to the rim of a glioma (labeled with bisbenzamide) & along which intensity profiles were measured. f, g Tom20 & GAPDH fluorescence along such a strip (barely visible without enhancement). The graphs show the raw intensity values given by ImageJ. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/26032618), licensed under a CC-BY license. Not internally tested by Novus Biologicals. Western Blot: GAPDH Antibody [NB300-320] - CDC20B was the protein effector regulated by hsa-miR-633. (a) CDC20B level was up-regulated after ox-LDL treatment revealed by Western blotting. (b) CDC20B level was decreased after the treatment of hsa-miR-633 mimics revealed by Western blotting. (c) CDC20B level was increased after the treatment of Ki-67 hsa-miR-633 inhibitor revealed by Western blotting. (d) The luciferase reporter plasmids were constructed as illustrated. (e) Relative luciferase activities after co-transfection CDC20B WT & hsa-miR-633/Control, or CDC20B Mut & hsa-miR-633/Control were measured. (f) The expression PCNA levels of two proliferation markers, Ki67 & PCNA after the treatment of si-CDC20B were measured using Western blotting. (g) Colony formation assay was conducted to examine the proliferation abilityafter the Control C208 GAPDH treatment of si-CDC20B. (h) Transwell migration & invasion assays were conducted to examine the migration & invasion abilities of VSMCs after the treatment of si-CDC20B. (i) Quantification results of (g). (j) Quantification results of (h). *P < 0.05, **P < 0.01, ***P < 0.001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35212610), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Simple Western: GAPDH Antibody [NB300-320] - MiR-34a affects stroke D. outcomes via interacting with cytochrome c. (A) WES system image showing CYC, VDAC & GAPDH expression from hemispheres of WT & miR-34a-/- mice at 6 h post-stroke. (B) Relative CYC expression normalized to GAPDH from the data generated by the WES system. CYC level is significantly decreased in ischemic hemispheres of WT mice but no significant changes in miR-34a-/- mice between contralateral hemispheres (Control) & ischemic hemispheres (Ischemia). N = 5 per group, **p < 0.01, One-way ANOVA followed by post hoc Tuckey's test was used for data analysis. Data are expressed as mean ± S.D. (C) Relative VDAC expression normalized to GAPDH from the data generated by the WES system. VDAC was not significantly altered in WT mice nor miR-34a-/- mice. (D) Multiplexed WES system image showing CYC & GAPDH expression from purified pCECs of WT & miR-34a-/mice (n = 10 per group, pooled cell samples) at 6 h post-stroke. (E) Relative CYC expression by normalization to GAPDH. A 2.8 fold decrease of CYC level was observed in WT mice but no changes were observed in miR-34a-/- mice between contralateral hemispheres & ischemic hemispheres. (F) A CYC reporter was coexpressed with a miR-34a plasmid, a miR-34a mimic, a miR-34c mimic, or a plasmid control in cultured cerebral vascular endothelial cells for 24 hours. Relative firefly luciferase activity was evaluated & normalized to renilla luciferase activity. Relative firefly luciferase activity was reduced by miR-34a plasmid & miR-34a mimic. The experiment was repeated 3 times & triplicates were used for each analysis. Data represents the mean \pm S.D. *p < 0.05. One-way ANOVA followed by post-hoc Tuckey's test was used for analysis. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/32094435), licensed under a CC-BY license. Not internally tested by Novus Biologicals. Western Blot: GAPDH Antibody [NB300-320] - Hsa-miR-633 inhibitor could reverse the si-circ 0008896 phenotypes. (a) CCK8 assav was conducted to measure cell viability after up-regulation of hsa-miR-633. (b) The expression levels of two proliferation markers, Ki67 & PCNA after up-regulation of hsa-miR-633 were measured using Western blotting. (c) CCK8 assay was conducted to measure cell viability after the treatment of si-circ0008896, hsa-miR-633 inhibitor & si-circ0008896+ hsa-miR-633 inhibitor. (d) The expression levels of two proliferation markers, Ki67 & PCNA after the treatment of si-circ0008896, hsa-miR-633 inhibitor & sicirc0008896+ hsa-miR-633 inhibitor were measured using Western blotting. (e) Colony formation assay was conducted to examine proliferation ability number of colonies after the treatment of sicirc0008896, hsa-miR-633 inhibitor & si-circ0008896+ hsa-miR-633 inhibitor. (f) Quantification results of (e). (g) Transwell migration & invasion assays were conducted to examine the migration & invasion abilities of VSMCs after the treatment of si-circ0008896, hsa-miR-633 inhibitor & si-circ0008896+ hsa-miR-633 inhibitor. (h) Quantification results of (g). *P < 0.05, **P < 0.01, ***P < 0.001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35212610), licensed under a CC-BY

license. Not internally tested by Novus Biologicals.

Page 5 of 10 v.20.1 Updated 4/13/2025





Western Blot: GAPDH Antibody [NB300-320] - Down-regulation of hsa_circ_0008896 inhibited proliferation, migration & invasion in vitro. (a) The expression level of hsa circ 0008896 after si-circ 0008896 transfection was detected using quantitative PCR. (b) CCK8 assay was conducted to measure cell viability after down-regulation of hsa circ 0008896. (c) The expression levels of two proliferation markers, Ki67 & PCNA after down-regulation of hsa_circ_0008896 were detected using Western blotting. (d) Colony formation assay was conducted to examine proliferation ability after down-regulation of hsa_circ_0008896. (e) The quantification results of (d). (f) Transwell migration & invasion assays were conducted to examine the migration & invasion abilities of VSMCs after down-regulation of hsa circ 0008896. (g) The quantification results of (f). *P < 0.05, **P < 0.01, ***P < 0.001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35212610), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GAPDH Antibody [NB300-320] - CDC20B was the protein a effector regulated by hsa-miR-633. (a) CDC20B level was up-regulated after ox-LDL treatment revealed by Western blotting. (b) CDC20B level was decreased after the treatment of hsa-miR-633 mimics revealed by Western blotting. (c) CDC20B level was increased after the treatment of hsa-miR-633 inhibitor revealed by Western blotting. (d) The luciferase reporter plasmids were constructed as illustrated. (e) Relative luciferase activities after co-transfection CDC20B WT & hsa-miR-633/Control, or CDC20B Mut & hsa-miR-633/Control were measured. (f) The expression levels of two proliferation markers, Ki67 & PCNA after the treatment of si-CDC20B were measured using Western blotting. (g) Colony formation assay was conducted to examine the proliferation abilityafter the treatment of si-CDC20B. (h) Transwell migration & invasion assays were conducted to examine the migration & invasion abilities of VSMCs after the treatment of si-CDC20B. (i) Quantification results of (g). (j) Quantification results of (h). *P < 0.05, **P < 0.01, ***P < 0.001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35212610), licensed under a CC-BY license. Not internally tested by Novus Biologicals.







Simple Western: GAPDH Antibody [NB300-320] - MiR-34a affects stroke Marker (kDa) outcomes via interacting with cytochrome c. (A) WES system image 66 showing CYC, VDAC & GAPDH expression from hemispheres of WT & 40 miR-34a-/- mice at 6 h post-stroke. (B) Relative CYC expression normalized to GAPDH from the data generated by the WES system. CYC level is significantly decreased in ischemic hemispheres of WT mice but no significant changes in miR-34a-/- mice between contralateral hemispheres (Control) & ischemic hemispheres (Ischemia). N = 5 per group, **p < 0.01, One-way ANOVA followed by post hoc Tuckey's test was used for data analysis. Data are expressed as mean ± S.D. (C) Relative VDAC expression normalized to GAPDH from the data generated by the WES system. VDAC was not significantly altered in WT mice nor miR-34a-/- mice. (D) Multiplexed WES system image showing CYC & GAPDH expression from purified pCECs of WT & miR-34a-/mice (n = 10 per group, pooled cell samples) at 6 h post-stroke. (E) Relative CYC expression by normalization to GAPDH. A 2.8 fold decrease of CYC level was observed in WT mice but no changes were observed in miR-34a-/- mice between contralateral hemispheres & ischemic hemispheres. (F) A CYC reporter was coexpressed with a miR-34a plasmid, a miR-34a mimic, a miR-34c mimic, or a plasmid control in cultured cerebral vascular endothelial cells for 24 hours. Relative firefly luciferase activity was evaluated & normalized to renilla luciferase activity. Relative firefly luciferase activity was reduced by miR-34a plasmid & miR-34a mimic. The experiment was repeated 3 times & triplicates were used for each analysis. Data represents the mean \pm S.D. *p < 0.05. One-way ANOVA followed by post-hoc Tuckey's test was used for analysis. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/32094435), licensed under a CC-BY license. Not internally tested by Novus Biologicals. Western Blot: GAPDH Antibody [NB300-320] - Hsa-miR-633 inhibitor b could reverse the si-circ 0008896 phenotypes. (a) CCK8 assay was conducted to measure cell viability after up-regulation of hsa-miR-633. (b) The expression levels of two proliferation markers, Ki67 & PCNA after up-regulation of hsa-miR-633 were measured using Western blotting. (c) CCK8 assay was conducted to measure cell viability after the treatment of si-circ0008896, hsa-miR-633 inhibitor & si-circ0008896+ hsa-miR-633 inhibitor. (d) The expression levels of two proliferation markers, Ki67 & PCNA after the treatment of si-circ0008896, hsa-miR-633 inhibitor & sicirc0008896+ hsa-miR-633 inhibitor were measured using Western blotting. (e) Colony formation assay was conducted to examine proliferation ability number of colonies after the treatment of sicirc0008896, hsa-miR-633 inhibitor & si-circ0008896+ hsa-miR-633 inhibitor. (f) Quantification results of (e). (g) Transwell migration & invasion assays were conducted to examine the migration & invasion s abilities of VSMCs after the treatment of si-circ0008896, hsa-miR-633 inhibitor & si-circ0008896+ hsa-miR-633 inhibitor. (h) Quantification results of (g). *P < 0.05, **P < 0.01, ***P < 0.001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35212610), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Page 7 of 10 v.20.1 Updated 4/13/2025





Publications

Mozin E, Massouridès E, Mournetas V, Lièvre C et Al. Dystrophin deficiency impairs cell junction formation during embryonic myogenesis from pluripotent stem cells iScience 2024-07-23 [PMID: 39040067]

I Liebold, S Meyer, M Heine, A Kuhl, J Witt, L Eissing, AW Fischer, AC Koop, J Kluwe, JSZ Wiesch, M Wehmeyer, U Knippschil, L Scheja, J Heeren, L Bosurgi, A Worthmann TREM2 Regulates the Removal of Apoptotic Cells and Inflammatory Processes during the Progression of NAFLD Cells, 2023-01-17;12(3):. 2023-01-17 [PMID: 36766683]

Renz C, Asimaki E, Meister C et Al. Ubiquiton-An inducible, linkage-specific polyubiquitylation tool Mol Cell 2024-01-18 [PMID: 38103558]

Chen, X;Wang, F;Tang, J;Meng, J;Han, Z; Paralemmin-3 augments lipopolysaccharide-induced acute lung injury with M1 macrophage polarization via the notch signaling pathway Respiratory physiology & neurobiology 2023-12-14 [PMID: 38103708]

Christoph Kuppe, Mahmoud M Ibrahim, Jennifer Kranz, Xiaoting Zhang, Susanne Ziegler, Javier Perales-Patón, Jitske Jansen, Katharina C. Reimer, James R. Smith, Ross Dobie, John R. Wilson-Kanamari, Maurice Halder, Yaoxian Xu, Nazanin Kabgani, Nadine Kaesler, Martin Klaus, Lukas Gernhold, Victor G. Puelles, Tobias B. Huber, Peter Boor, Sylvia Menzel, Remco M. Hoogenboezem, Eric M.J. Bindels, Joachim Steffens, Jürgen Floege, Rebekka K Schneider, Julio Saez-Rodriguez, Neil C Henderson, Rafael Kramann Decoding myofibroblast origins in human kidney fibrosis Nature 2021-08-23 [PMID: 33176333]

Yamada T, Yoshinari Y, Tobo M et al. Nac? protects the larval fat body from cell death by maintaining cellular proteostasis in Drosophila Nature communications 2023-09-01 [PMID: 37658058] (WB, Drosophila)

Haykal M, Rodrigues-Ferreira S, Nahmias C Aneuploidy triggers vulnerability to WEE1 inhibition via severe chromosome pulverization bioRxiv 2023-09-19 (WB, Human)

Lemma RB, Ledsaak M, Fuglerud BM et al. MYB regulates the SUMO-protease SENP1 and its novel interaction partner UXT - modulating MYB target genes and the SUMO landscape The Journal of biological chemistry 2023-07-17 [PMID: 37468105] (WB, Human)

Renz C, Asimaki E, Meister C et al. Ubiquiton - An Inducible, Linkage-Specific Polyubiquitylation Tool Available at SSRN 2023-04-18 (WB, Human)

Udayakumar PD Dissecting the transactivation domain (tAD) of the transcription factor c-Myb to assess recent models of tAD function FEBS Open Bio 2020-09-16 [PMID: 32937031]

Krohn L The genetics of REM sleep behavior disorder and its conversion to overt neurodegeneration Thesis (WB, Human)

Winnica DE, Monzon A, Ye S et al. Airway epithelial Paraoxonase-2 in obese asthma PloS one 2022-03-14 [PMID: 35286330] (WB, Human)

More publications at http://www.novusbio.com/NB300-320





Novus Biologicals USA

10730 E. Briarwood Avenue Centennial, CO 80112 USA Phone: 303.730.1950 Toll Free: 1.888.506.6887 Fax: 303.730.1966 nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave Toronto, ON M8Z 4E6 Canada Phone: 905.827.6400 Toll Free: 855.668.8722 Fax: 905.827.6402 canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane Abingdon Science Park Abingdon, OX14 3NB, United Kingdom Phone: (44) (0) 1235 529449 Free Phone: 0800 37 34 15 Fax: (44) (0) 1235 533420 info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com Technical Support: nb-technical@biotechne.com Orders: nb-customerservice@bio-techne.com General: novus@novusbio.com

Products Related to NB300-320

NB410-28088-1mg	Peroxidase)] Goat IgG Isotype Control
	Denkey anti Coat IaC Secondary Antibedy [HPR (Hercoradish
HAF017	Rabbit anti-Goat IgG Secondary Antibody [HRP (Horseradish Peroxidase)]
NBL1-10967	GAPDH Overexpression Lysate

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NB300-320

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications



www.novusbio.com



technical@novusbio.com